At a glance
- Originator Sanofi-Synthelabo
- Class Antidementias; Neuroprotectants
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 12 Aug 1996 Discontinued-Preclinical for Cognition disorders in France (Unknown route)